Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
August 23rd 2024Acute lymphoblastic leukemia specialists explore resources and strategies to address the logistical hurdles of CAR-T therapy implementation, while also examining patient support programs designed to enhance treatment accessibility and adherence.
Read More
Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy
August 8th 2024The panel examines their strategies for consolidation or maintenance treatment following CAR T-cell therapy, while also considering whether CAR T-cell therapy can function as a standalone treatment modality.
Read More
Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL
August 1st 2024The panel explores the potential impact of obecabtagene autoleucel on the treatment landscape and decision-making process for acute lymphoblastic leukemia, contingent upon its FDA approval.
Read More
Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
August 1st 2024A medical expert reviews the FELIX study, highlighting its key findings and characteristics while comparing and contrasting it with the ZUMA-3 trial in the context of CAR T-cell therapy for acute lymphoblastic leukemia.
Read More
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
July 18th 2024The panel evaluates key patient characteristics and clinical factors influencing the decision to recommend CAR T-cell therapy as a treatment option in relapsed or refractory acute lymphoblastic leukemia.
Read More
Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
July 11th 2024The panel examines the current positioning of CAR T-cell therapy within the treatment paradigm for Relapsed / Refractory Acute Lymphoblastic Leukemia, considering the distinctions between Philadelphia chromosome-positive and negative patients.
Read More
CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
June 27th 2024Dr. Lori Muffly explains the general mechanism of action in CAR T-cell therapy and compares the distinct features of Brexucabtagene autoleucel (Brexu-cel), Tisagenlecleucel (Tisa-cel), and Obecabtagene autoleucel (Obe-cel).
Read More
Emerging Therapies for the Older Patient With Acute Lymphoblastic Leukemia
February 16th 2024Dr. Shah and faculty provide updates on emerging therapies, which exhibit promise for the treatment of relapsed or refractory acute lymphoblastic leukemia such as tisagenlecleucel and Obe-cel; obecabtagene autoleucel, preliminary outcomes of which were presented in the FELIX study at the 65th ASH Annual Meeting.
Read More
Optimal Sequencing of Therapy for Previously Treated Patients With Relapsed or Refractory ALL
February 16th 2024Dr. Shah and colleagues dissect the social determinants of health, including limited personal resources, frailty, distance to treatment facilities, therapeutic compliance, and other considerations that impact effective treatment sequencing for patients with relapsed or refractory ALL, including access to care and CAR-T cell availability.
Read More
Influences on Treatment Response and Survival in Recipients of Brexucabtagene Autoleucel Therapy
February 9th 2024Dr. Park and co-panelists review the patient and disease characteristics, including patient age, high pre-apheresis disease burden, and bridging response to inotuzumab or blinatumomab among other variables that might best support consideration of post-CART19 maintenance therapy.
Read More
Standardizing and Optimizing Bridging Strategies Prior to CAR-T Infusion
February 2nd 2024Dr. Roloff and colleagues offer expert opinion on optimizing treatment sequences for patients with relapsed or refractory ALL who have received two or more prior lines of therapy and the disease and patient factors that inform their treatment plans.
Read More
Objectives, Clinical Endpoints, and Safety Profile of the Phase 2 ZUMA-3 Clinical Trial
January 26th 2024Dr. Bijal and colleagues discuss the objectives, clinical outcomes, and safety profile of the Phase 2 ZUMA 3 clinical trial, which evaluated treatment of adult patients with relapsed or refractory, B-precursor, acute lymphoblastic leukemia with the anti-CD-19/anti-CD20 bispecific CAR-T cell therapy, KTE-X19 (brexucabtagene autoleucel).
Read More
Overview of the Current State of CART19 Therapy for Adult Patients With R/R ALL
January 26th 2024Drs. Roloff, Park, and Shah provide a brief overview of the current, CAR-T cell therapeutic landscape for relapsed or refractory acute lymphoblastic leukemia in adults with a particular focus on those who have completed two or more lines of prior therapy.
Read More
Objectives of the 2023 ASH Insights Program on CAR-T Cell Therapy for Adult B Cell ALL
January 26th 2024Faculty review the objectives of the 2023 ASH Insights Program on the Efficacy and Safety of Brexucabtagene Autoleucel CART19 Cell Therapy in Adults with Advanced Acute Lymphoblastic Leukemia.
Read More